anti-scl-70 autoantibodies

Also Known As:

Anti-Scl-70 antibodies; Anti-Scl-70 antibody; Anti-Scl-70 autoantibody; Anti-Scl70 antibodies; Anti-Scl70 antibody; Anti-Scl70 autoantibodies; Anti-scleroderma-70 antibodies; Anti-scleroderma-70 autoantibodies; anti-topoisomerase I antibodies; anti-topoisomerase I antibody; anti-topoisomerase I autoantibodies; anti-topoisomerase I autoantibody

Networked: 201 relevant articles (4 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sato, Shinichi: 8 articles (01/2017 - 06/2004)
2.	Sato, S: 8 articles (12/2009 - 04/2001)
3.	Takehara, K: 8 articles (12/2009 - 04/2001)
4.	Takehara, Kazuhiko: 7 articles (08/2019 - 06/2004)
5.	Hasegawa, Minoru: 7 articles (01/2017 - 06/2004)
6.	Yanaba, Koichi: 7 articles (05/2015 - 04/2005)
7.	Hasegawa, M: 6 articles (12/2009 - 04/2001)
8.	Allanore, Y: 5 articles (01/2019 - 01/2009)
9.	Asano, Yoshihide: 5 articles (01/2017 - 08/2010)
10.	Fujimoto, Manabu: 5 articles (01/2017 - 01/2010)

Related Diseases

1.	Connective Tissue Diseases (Connective Tissue Disease) 09/01/1997 - "ACA were present in 5% and anti-Scl-70 antibodies were present in 2% of patients with other connective tissue diseases, but fewer than 1% of disease free controls had either antibody present. " 09/01/2007 - "Once anti-Scl-70 antibody was detected the patient was transferred to the Department of Rheumatology and Connective Tissue Diseases. " 12/01/2016 - "He also tested positive for anti-topoisomerase I antibodies without clinical diagnosis of any connective tissue disease, including systemic sclerosis. " 02/11/1989 - "The diagnostic and prognostic value of anti-Scl-70 autoantibodies in systemic scleroderma and other connective tissue diseases was investigated. " 01/01/2003 - "Anti-centromere antibodies (ACA) and anti-Scl-70 antibodies are very useful in distinguishing patients with systemic sclerosis (SSc) from healthy controls, from patients with other connective tissue disease, and from unaffected family members. "
2.	Systemic Scleroderma (Systemic Sclerosis) 02/01/2013 - "The aim of the present study was to clarify the clinical significance of anti-topoisomerase I antibody (Ab) levels in Japanese patients with systemic sclerosis (SSc). " 01/01/2023 - "Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies." 11/28/2022 - "Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort." 10/01/2022 - "To determine if some patients who tested positive for anti-Scl-70 antibody in clinical practice, but did not have classifiable systemic sclerosis, were negative for anti-Scl-70 antibody by the more specific immunodiffusion method of testing. " 05/01/2020 - "Smoking and systemic sclerosis: influence on microangiopathy and expression of anti-topoisomerase I antibodies in a monocentric cohort."
3.	Fibrosis (Cirrhosis) 01/01/2023 - "The only independent factor for the onset of skin fibrosis in ssSSc was the positivity for anti-Scl-70 antibodies (odds ratio, 3.078; 95% CI, 1.227-7.725; P = .02). " 03/31/2021 - " factors such as age, FVC, extent of fibrosis and presence of anti-topoisomerase I antibodies can help predict progression of SSc-ILD, though composite risk scores may offer greater predictive power. " 01/01/2019 - "Elevated serum E2 levels in dcSSc males are associated with heart involvement, trend to progression of dermal fibrosis, and, if anti-Scl-70 antibody positive, worse survival. " 01/01/2018 - "In the Oslo cohort, CX3CL1 correlated with anti-Topoisomerase-I-antibody and lung fibrosis. " 12/01/1995 - "The patients with dSSc and elevated serum TIMP-1 levels showed a significantly greater incidence of lung fibrosis and anti-topoisomerase I antibody than those with normal serum TIMP-1 levels. "
4.	Sclerosis 05/01/2014 - "This treatment improved ILD and SLE activities, along with reduction of dermal sclerosis and serum anti-topoisomerase I antibody levels. " 05/01/2008 - "Clinical features were not associated with the incidence of PF in patients with SSc and anti-topoisomerase I antibodies, although severe skin sclerosis was correlated with the presence of PF in patients with ACA. " 01/01/1991 - "Patients with anti-Scl-70 antibody represented one fourth of the cases and had the fastest progression, developing sclerosis in less than 5 years after the onset of Raynaud's phenomenon. " 07/01/2014 - "The demographic and clinical features of the SSc patients showed that young age, male sex, anti-topoisomerase I antibody positivity, severe skin sclerosis, interstitial lung disease complication and cardiac involvements were significantly prevalent in patients with DU. " 01/01/2010 - "Re-emergence of anti-topoisomerase I antibody with exacerbated development of skin sclerosis in a patient with systemic sclerosis."
5.	Interstitial Lung Diseases (Interstitial Lung Disease) 01/01/2019 - "Furthermore, in contrast to several other studies, the diffuse type of scleroderma was more commonly observed than the limited type, which resulted in a high frequency of anti-Scl-70 antibody and interstitial lung disease." 12/01/2009 - "This study confirms the association between an SNP in the CTGF gene and susceptibility to SSc, especially in the presence of diffuse cutaneous SSc, interstitial lung disease and anti-topoisomerase I antibody. " 01/01/2023 - "Patients with DUs had higher mean mRSS, lover mean FVC and more frequently diffuse disease, interstitial lung disease, anti-SCL70 antibody positivity (p < 0.05 for all). " 01/14/2021 - "Data from 20 severe patients (18 females and 2 males, mean age 66.7 ± 11.0 years) with diffuse SSc (anti-topoisomerase I antibody in 95%) patients with multiorgan involvement including interstitial lung disease (ILD) treated with an IBCDT were prospectively collected. " 07/16/2020 - "IPF patients with severely affected respiratory capacities and late-stage SSc patients presenting anti-topoisomerase I antibodies and interstitial lung disease showed the highest SCX-serum levels. "

Related Drugs and Biologics

1.	anticentromere antibody
2.	Tissue Inhibitor of Metalloproteinase-1
3.	Antibodies
4.	Autoantibodies
5.	Antinuclear Antibodies
6.	trioctyl phosphine oxide (TOPO)
7.	Anti-Idiotypic Antibodies
8.	alpha-Tocopherol
9.	Ascorbic Acid (Vitamin C)
10.	RNA Polymerase III

Related Therapies and Procedures

1.	Microspheres (Microsphere)
2.	Therapeutics
3.	Stem Cell Transplantation
4.	Transplantation
5.	Drug Therapy (Chemotherapy)